EpilepsyGTx raises $33 million Series A for epilepsy gene therapy

EpilepsyGTx raised $33 million in Series A funding. XGEN Venture, British Business Bank invested. Funds advance EPY201 through Phase I/IIa trials.

Funding details: $33 million (Series A)

Full Story

EpilepsyGTx raised $33 million in Series A funding. Investors include XGEN Venture, the British Business Bank, and a global biopharma company. The round follows $10 million in pre-seed and seed from UCL Technology Fund and others.

The money supports first-in-human Phase I/IIa trials for EPY201. This AAV gene therapy treats focal refractory epilepsy. It reduces hyperexcitability at the seizure focus with local delivery. Patients could gain seizure freedom from one treatment, skipping surgery or long-term drugs.

EpilepsyGTx plans a pipeline of gene therapies for refractory epilepsy and hyperexcitability disorders. EPY201 uses AAV9 capsid, CAMK2A promoter, and engineered Kv1.1 channel via intraparenchymal administration. Focal epilepsy starts in one brain area and resists two or more antiseizure meds.

Nicolas Koebel, CEO, said refractory epilepsy hits millions with dangerous seizures. EPY201 could stop them with one minimally invasive dose. It shifts how this condition gets treated after decades.

EpilepsyGTx develops gene therapies for refractory epilepsy. Based in London, UK, it targets focal cases where seizures resist standard drugs. The lead program EPY201 and pipeline aim at neuronal hyperexcitability disorders for better patient outcomes.

Details from FinSMEs.